Wordt geladen...
Cost-Utility Analysis: Current Methodological Issues and Future Perspectives
The use of cost–effectiveness as final criterion in the reimbursement process for listing of new pharmaceuticals can be questioned from a scientific and policy point of view. There is a lack of consensus on main methodological issues and consequently we may question the appropriateness of the use of...
Bewaard in:
| Hoofdauteurs: | , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Frontiers Research Foundation
2011
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3113167/ https://ncbi.nlm.nih.gov/pubmed/21713127 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2011.00029 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|